DiObex Scores $24 Million

DiObex Inc., a San Francisco-based drug company focused on metabolic disorders like Type II diabetes, has raised $24 million in Series B funding. Inventages Venture Capital led the deal, and was joined by Mitsui & Co., Pac-Link BioVentures and return backers Domain Associates, Pequot Ventures and Sofinnova Ventures. www.diobex.com